Bolt - BOLT

Bolt Biotherapeutics Azioni (NASDAQ: BOLT)

Ultime notizie per Bolt Biotherapeutics (NASDAQ:BOLT) Azioni

Bolt Biotherapeutics

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics Inc

BOLT

Bolt Metals Corp

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings Inc

HC Wainwright &amp; Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Neutral.

News

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 16.67 percent decrease over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $1.27 million which beat the analyst consensus estimate of $891.50 thousand by 43.02 percent. This is a 11.03 percent decrease over sales of $1.43 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Bolt Biotherapeutics Q2 EPS $(0.56) Misses $(0.48) Estimate, Sales $1.27M Beat $891.50K Estimate

Shares of Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) fell sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/quote/BOLT/earnings">first-quarter financial results</a>.
Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5.
Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AERWINS Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) shares surged 201% to $8.16.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) jumped 169% to $0.1449 after jumping over 41% on Tuesday. SINTX Technologies recently posted downbeat quarterly results.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) jumped 87% to $0.5336 after jumping around 368% on Tuesday.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 53.2% to $6.54 following first-quarter results.</li>
<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) gained 53% to $1.36 after the company reported better-than-expected third-quarter financial results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) jumped 51% to $0.0850.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares gained 41% to $0.0627 after surging 7% on Tuesday.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) gained 30.6% to $0.90. Complete Solaria signed a term sheet to eliminate Carlyle debt.</li>
<li>OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) jumped 24% to $13.03 following upbeat quarterly results.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) rose 23% to $0.0686.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) jumped 21.5% to $220.93 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) gained 21.4% to $3.85.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) rose 20% to $6.44.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) rose 16.5% to $9.47 after the company reported better-than-expected first-quarter financial results.</li>
<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) rose 15.4% to $1.2999 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) jumped 14.3% to $7.98 following first-quarter results.</li>
<li>Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) gained 13.5% to $4.34.</li>
<li>Riskified Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) jumped 12.8% to $6.05 following upbeat results.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) gained 12.8% to $12.66 following first-quarter results.</li>
<li>Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) jumped 12% to $0.2530.</li>
<li>B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) rose 11.5% to $9.53.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 11.2% to $0.0529.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 8.1% to $0.0637 after adding around 12% on Tuesday.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) rose 6% to $142.18 after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $128 to $152.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 63.9% to $0.8199 after the company reported pricing of $2.25m public offering.</li>
<li>Yield10 Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) fell 49.4% to $2.66 after the company reported delisting from the Nasdaq.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 45.8% to $0.4604 after the company announced pricing of $4.7 million public offering.</li>
<li>Pixelworks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) dipped 40.2% to $1.1186 after the company issued soft second-quarter guidance.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 31.9% to $33.22 following a 60% surge on Tuesday.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) dipped 31% to $4.24.</li>
<li>VirTra, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares fell 30% to $11.49 after the company reported worse-than-expected first-quarter financial results.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) dipped 30.3% to $2.25.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares fell 29.6% to $3.0896. Wolfe Research analyst Steve Fleishman downgraded SunPower from Peer Perform to Underperform.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined 28.7% to $1.84 after the company reported downbeat first-quarter sales.</li>
<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) fell 27.5% to $9.84 after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood of coming in towards the lower end of its guidance range.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 26.3% to $5.04 after jumping 32% on Tuesday.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) declined 25% to $2.7550.</li>
<li>The Oncology Institute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) fell 24.4% to $0.6798 following weak quarterly results.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 23.2% to $4.92 after jumping 442% on Tuesday. The company priced a follow-on offering for gross proceeds of $8.19 million.</li>
<li>Nortech Systems Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) fell 21.1% to $11.97. Nortech Systems is expected to hold a conference call on Thursday, May 16, to discuss the company&#8217;s first quarter financial results.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) fell 16.5% to $1.06.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 12.5% to $11.80.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) declined 12.1% to $6.74. Pulse Biosciences named Burke T. Barrett as President and Chief Executive Officer.</li>
<li>iRobot Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) fell 11.8% to $11.24.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) fell 10.2% to $3.11.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 9.9% to $4.8000.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) dipped 9.5% to $5.24. New reports indicate the company on Wednesday launched its first vehicle under its new Onvo brand.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) fell 8.7% to $10.22.</li>
<li>Petróleo Brasileiro S.A. &#8211; Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) shares fell 8.3% to $15.30. Brazil's President Luiz Inacio Lula da Silva fired Jean Paul Prates, the CEO of Petrobras, following a dispute over dividend.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38844468/jim-cramer-this-industrial-company-is-absolutely-terrific-recommends-buying-modine-manufacturing">Jim Cramer: This Industrial Company Is &#8216;Absolutely Terrific&#8217;, Recommends Buying Modine Manufacturing</a>

Intraday Update

Markets

Movers

AEMD

ARQT

AWIN

BCRX

BSFC

CABA

CDRO

CRKN

CSLR

CTNT

DELL

DLPN

EDBL

FFIE

GWAV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INTZ

IRBT

JFBR

KOSS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MNDY

NOVA

NSYS

NTRB

NVAX

OPRX

PEGY

PLSE

PXLW

RIVN

RSKD

SINT

SLNA

SPCE

SPWR

VRPX

VTSI

YTEN

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Outperform to Market Perform and lowers the price target from $3 to $1.

Downgrades

Price Target

Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $1

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares moved upwards by 22.8% to $12.87. The market value of their outstanding shares is at $234.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 20.57% to $1.0. The market value of their outstanding shares is at $50.7 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 67.0% to $0.76 during Wednesday's regular session. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 50.35% to $0.42. The company's market cap stands at $1.1 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock decreased by 37.84% to $3.27. The company's market cap stands at $2.1 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares declined by 33.12% to $0.88. The company's market cap stands at $33.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.91% to $0.73. The market value of their outstanding shares is at $54.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares declined by 18.27% to $1.61. The market value of their outstanding shares is at $3.6 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

EYEN

TCON

TTOO

12 Health Care Stocks Moving In Wednesday's Intraday Session

Jones Trading analyst Soumit Roy downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Hold.

Jones Trading Downgrades Bolt Biotherapeutics to Hold

HC Wainwright &amp; Co. analyst Edward White downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Neutral.

HC Wainwright & Co. Downgrades Bolt Biotherapeutics to Neutral

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Deutsche Bank analyst Bryan Keane downgraded the rating on Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) from Buy to Hold, while slashing the price target from $409 to $295. Accenture shares declined 0.2% to close at $306.95 on Tuesday. <a href="https://www.benzinga.com/quote/ACN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel analyst Stephen Willey downgraded Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares slipped 0.8% to settle at $1.32 on Tuesday. <a href="https://www.benzinga.com/quote/BOLT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Steve Fleishman downgraded the rating for SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) from Peer Perform to Underperform. SunPower shares jumped 59.6% to settle at $4.39 on Tuesday. <a href="https://www.benzinga.com/quote/SPWR/analyst-ratings">See how other analysts view this stock. See how other analysts view this stock.</a></li>
<li>B. Riley Securities analyst Lucas Pipes downgraded A-Mark Precious Metals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) from Buy to Neutral, but maintained the price target of $33. A-Mark Precious Metals shares gained 7.2% to close at $39.80 on Tuesday. <a href="https://www.benzinga.com/quote/AMRK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Chris Woronka downgraded the rating for Six Flags Entertainment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIX#NYSE">SIX</a>) from Buy to Hold, while lowering the price target from $29 to $27. Six Flags Entertainment shares slipped 0.6% to settle at $26.72 on Tuesday. <a href="https://www.benzinga.com/quote/SIX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38839679/top-3-consumer-stocks-that-could-blast-off-this-month">Top 3 Consumer Stocks That Could Blast Off This Month</a>

Trading Ideas

AMRK

This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/general/biotech/24/05/38830997/arcutis-biotherapeutics-stock-climbs-after-blockbuster-q1-results">first-quarter financial results</a>.
Arcutis Biotherapeutics reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents. Quarterly sales clocked in at $49.57 million, beating the analyst consensus estimate of $14.68 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Arcutis Biotherapeutics shares jumped 29% to $10.49 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 113.8% to $0.6098 in pre-market trading after jumping around 368% on Tuesday.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) gained 94.8% to $0.1072 in pre-market trading after jumping over 41% on Tuesday. SINTX Technologies recently posted downbeat quarterly results.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares gained 41.8% to $0.0631 in pre-market trading after surging 7% on Tuesday.</li>
<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) rose 28.8% to $1.45 in today's pre-market trading after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 17.7% to $0.0560 in pre-market trading.</li>
<li>Bitfarms Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) shares rose 16.2% to $1.87 in pre-market trading.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 14.6% to $0.0675 in pre-market trading after adding around 12% on Tuesday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares climbed 12.1% to $54.64 in pre-market trading following a 60% surge on Tuesday.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) gained 10.6% to $7.58 in pre-market trading after jumping 32% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined 40.1% to $1.36 in pre-market trading after dipping 20% on Tuesday. Virpax Pharmaceuticals recently reported a year-over-year decrease in first-quarter EPS results.</li>
<li>Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares fell 31.8% to $0.9008 in pre-market trading after the company reported first-quarter financial results.</li>
<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) fell 26.7% to $9.95 in pre-market trading after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood of coming in towards the lower end of its guidance range.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined 25.2% to $1.93 in pre-market trading after the company reported downbeat first-quarter sales.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 25.2% to $4.79 in pre-market trading after jumping 442% on Tuesday. The company priced a follow-on offering for gross proceeds of $8.19 million.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares dipped 21.8% to $0.6650 in pre-market trading after falling 14% on Tuesday.</li>
<li>VirTra, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares fell 20.5% to $13.05 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares fell 10.6% to $3.93 in pre-market trading after jumping around 60% on Tuesday.</li>
<li>Allogene Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) shares declined 8.8% to $2.70 in pre-market trading. Allogene Therapeutics filed for offering of up to 37.93 million shares of common stock.</li>
<li>Petróleo Brasileiro S.A. &#8211; Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) shares fell 8.6% to $15.25 in pre-market trading. Brazil's President Luiz Inacio Lula da Silva fired Jean Paul Prates, the CEO of Petrobras, following a dispute over dividend.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38835371/cisco-prestige-consumer-healthcare-and-3-stocks-to-watch-heading-into-wednesday">Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday</a>

Pre-Market Outlook

ALLO

BITF

Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock increased by 18.92% to $9.67. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) stock increased by 17.24% to $0.66. The market value of their outstanding shares is at $426.5 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) shares moved upwards by 15.45% to $3.66. The company's market cap stands at $49.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) shares increased by 15.11% to $0.47. The market value of their outstanding shares is at $2.2 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock rose 14.4% to $0.44. The market value of their outstanding shares is at $8.4 million. The company's, Q1 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 60.5% to $0.91 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock decreased by 29.56% to $0.93. The market value of their outstanding shares is at $35.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock decreased by 19.29% to $1.59. The market value of their outstanding shares is at $3.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock fell 18.48% to $2.03. The market value of their outstanding shares is at $6.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 17.78% to $0.7. The market value of their outstanding shares is at $1.8 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock declined by 13.45% to $0.29. The market value of their outstanding shares is at $42.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

DYNT

MPLN

RBOT

VIRI

VVOS

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

Bolt Biotherapeutics shares are trading lower after the company reported Q1 financial results. Also, multiple firms downgraded their respective price targets on the stock.

Guggenheim analyst Michael Schmidt downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Neutral.

Guggenheim Downgrades Bolt Biotherapeutics to Neutral

Stifel analyst Stephen Willey downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Hold and lowers the price target from $6 to $1.5.

Stifel Downgrades Bolt Biotherapeutics to Hold, Lowers Price Target to $1.5

Bolt Biotherapeutics shares are trading lower. The company reported Q1 financial results.

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.49) by 42.86 percent. The company reported quarterly sales of $5.30 million which beat the analyst consensus estimate of $2.06 million by 156.88 percent. This is a 190.25 percent increase over sales of $1.83 million the same period last year.

Bolt Biotherapeutics Q1 2024 GAAP EPS $(0.28) Beats $(0.49) Estimate, Sales $5.30M Beat $2.06M Estimate

<h3>Gainers</h3>
<ul>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 6.08% to $2.44. The market value of their outstanding shares is at $2.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock rose 5.81% to $0.06. The market value of their outstanding shares is at $7.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock fell 15.9% to $1.11 during Tuesday's after-market session. The market value of their outstanding shares is at $42.3 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock declined by 12.86% to $2.17. The company's market cap stands at $6.4 million. The company's, Q1 earnings came out today. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares decreased by 12.0% to $2.71. The company's market cap stands at $44.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) stock fell 7.66% to $66.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares decreased by 7.32% to $0.41. The market value of their outstanding shares is at $32.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.77% to $1.47. The market value of their outstanding shares is at $50.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

BCAB

IRIX

OCEA

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares rose 8.46% to $0.58. The company's market cap stands at $6.3 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares increased by 6.74% to $40.99. The market value of their outstanding shares is at $818.4 million. As per the news, the Q2 earnings report came out today. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares moved upwards by 6.66% to $1.44. The company's market cap stands at $54.9 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) shares increased by 6.66% to $1.76. The market value of their outstanding shares is at $2.6 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares rose 5.38% to $4.5. The company's market cap stands at $236.2 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) shares fell 10.8% to $1.9 during Wednesday's after-market session. The company's market cap stands at $104.6 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock fell 10.4% to $1.81. The market value of their outstanding shares is at $2.2 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares decreased by 8.54% to $2.25. The market value of their outstanding shares is at $181.8 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares declined by 8.51% to $0.64. The market value of their outstanding shares is at $22.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 7.33% to $2.53. The company's market cap stands at $9.2 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares declined by 6.33% to $6.07. The company's market cap stands at $5.3 million. As per the press release, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

CNTB

EIGR

HSDT

IPHA

12 Health Care Stocks Moving In Wednesday's After-Market Session

HC Wainwright &amp; Co. analyst Edward White maintains Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Buy and maintains $8 price target.

HC Wainwright & Co. Maintains Buy on Bolt Biotherapeutics, Maintains $8 Price Target

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 11.32 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $2.09 million which beat the analyst consensus estimate of $1.71 million by 22.16 percent. This is a 48.05 percent increase over sales of $1.41 million the same period last year.

Bolt Biotherapeutics Q4 EPS $(0.47) Beats $(0.48) Estimate, Sales $2.09M Beat $1.71M Estimate

Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody&trade; Immune-Stimulating Antibody Conjugate (ISAC), as a single agent and in combination with the HER2-targeting antibody pertuzumab.

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu

JonesTrading analyst Soumit Roy has maintained their neutral stance on BOLT stock, giving a Hold rating today. Soumit Roy has given his Hold rating...

Bolt Biotherapeutics: Hold Rating Amidst Restructuring and Pipeline Uncertainties

Bolt Biotherapeutics GAAP EPS of -$0.28, revenue of $5.3M

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Global stocks are surging. The MSCI ACWI Index, which encompasses both developed and emerging markets, reached another all-time high, continuing its record-breaking streak. This milestone is part of a broader trend in global equity markets, with 14 out of the world&rsquo;s 20 largest stock exchanges recently setting new records. In contrast to this general market uplift, stocks with analyst uncertainty remain a notable exception, where divergent views among experts signal potential volatility and risk for investors.



In the United States, the S&amp;P 500 and Nasdaq 100 indexes have also hit record levels, with the Dow Jones Industrial Average <a href="https://tokenist.com/why-the-dow-jones-industrial-average-just-hit-a-new-record-high/" target="_blank">surpassing the 40,000 mark</a> for the first time in history. This bullish momentum is mirrored across major markets in Europe, Canada, Brazil, India, Japan and Australia, where stock indices are either at or near their highest points.



Factors such as anticipated interest rate cuts, robust economies and strong corporate earnings propel the markets forward. Moreover, the presence of approximately $6 trillion in money market funds provides potential fuel for the rally to continue, with few apparent risks on the horizon.



The April downturn in global stocks was short-lived, as buyers quickly re-entered the market, contributing to the S&amp;P 500&rsquo;s longest stretch without a 2% decline since 2017-2018, lasting 311 days. Even Chinese equities, which have faced challenges since peaking in February 2021, show signs of recovery.



Investors hope the economy will remain robust while inflation decreases, leading to speculation that the Federal Reserve may relax monetary policy later in the year. As valuations increase, many analysts adjust their ratings to consider the latest stock prices. Along these lines, here are three stocks with analyst uncertainty to avoid, according to Wall Street analysts.



<h2>Bolt Biotherapeutics (BOLT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/medical-tools-tech-therapeutics-300x169.png" alt="An image of a tablet with 'therapeutics' on the screen, a stethoscope and face mask around it"><div>Source: ra2 studio/Shutterstock</div></div>Bolt Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bolt-stock-quote/">BOLT</a>) shares experienced <a href="https://seekingalpha.com/news/4106443-bolt-bio-stock-falls-portfolio-shakeup-prompts-downgrades" target="_blank">a series of downgrades</a> from various analysts following the discontinuation of its lead program, BDC-1001 and significant changes in strategy and management.&nbsp;



Leerink Partners shifted their rating from Outperform to Market Perform and adjusted the price target to $1.00 from the previous $3.00. The halt influenced the decision to develop BDC-1001, the company&rsquo;s lead immune-stimulating antibody conjugate (ISAC) and the subsequent corporate restructuring, which includes a 50% reduction in the workforce.



Guggenheim also downgraded Bolt Biotherapeutics from Buy to Neutral, removing their price target entirely. The analyst cited low visibility on the success probabilities of the company&rsquo;s remaining product candidates, BDC-3042 and BDC-4182, as a reason for the downgrade.



Stifel followed suit, lowering their rating from Buy to Hold and decreasing the price target to $1.50 from $6.00. Stifel&rsquo;s analyst highlighted the challenges facing Bolt, including skepticism about the monotherapy efficacy prospects of BDC-3042 and the competitive landscape for BDC-4182, an ISAC targeting claudin-18.2, which is expected to enter clinical trials in FY25.&nbsp;



Concerns were also raised about the potential safety profile of the next-generation platform, given the issues with toxicity in previous programs.&nbsp;



<h2>Under Armour (UAA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/01/uaa1600b-300x169.jpg" alt="the exterior of an Under Armour store"><div>Source: Sundry Photography / Shutterstock.com</div></div>Under Armour (NYSE:<a href="https://investorplace.com/stock-quotes/uaa-stock-quote/">UAA</a>) stock was downgraded at two sell-side brokers last week. JPMorgan (NYSE:<a href="https://investorplace.com/stock-quotes/jpm-stock-quote/">JPM</a>) shifted from a &lsquo;Neutral&rsquo; to an &lsquo;Underweight&rsquo; rating, with a revised price target set to $6.00, a decrease from the previous $8.00 target. In a separate move, William Blair downgraded Under Armor from &lsquo;Outperform&rsquo; to &lsquo;Market Perform.&rsquo;



The downgrade move reflects the company&rsquo;s forecast for fiscal year 2025, which includes an adjusted earnings per share (EPS) significantly lower than current market expectations, alongside anticipated revenue declines and margin pressures.



The analyst moves come after Under Armour management offered <a href="https://www.streetinsider.com/Earnings/Under+Armour+stock+tumbles+as+guidance+disappoints/23237392.html" target="_blank">a weaker-than-expected outlook</a>. On the top line, UAA sees revenue decline in the negative low-double-digits, which is less optimistic than the Street&rsquo;s forecast of a 2.4% year-over-year increase.&nbsp;



For the near-term outlook, Under Armour guided a diluted loss per share of -$0.08 to -$0.10 for the first quarter of 2025, in contrast to the Street&rsquo;s anticipated $0.04 EPS. This guidance is based on expected revenues to be down in the low-teens year-over-year, which is below the Street&rsquo;s estimate of a 0.1% decline and a predicted gross margin decrease of 20-30 basis points year-over-year, contrary to the Street&rsquo;s expectation of a 70 basis points increase.



<h2>Baidu (BIDU)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/02/bidu1600-2-1-300x169.png" alt="Laptop computer displaying logo of Baidu (BIDU), a Chinese multinational technology company specializing in Internet-related services and products"><div>Source: monticello / Shutterstock.com</div></div>Morgan Stanley (NYSE:<a href="https://investorplace.com/stock-quotes/ms-stock-quote/">MS</a>) <a href="https://finance.yahoo.com/news/baidu-ms-downgrades-equal-weight-022929238.html" target="_blank">lowered</a> its stance on Baidu (NASDAQ:<a href="https://investorplace.com/stock-quotes/bidu-stock-quote/">BIDU</a>), downgrading the stock from Overweight to Equal-weight and lowering the price target to $125 from the previous $140. Baidu, known for its dominant internet search engine in China, has expanded its business into cloud services and artificial intelligence. The shift in analyst ratings contributes to the volatility and places Baidu among the stocks with analyst uncertainty.



The broker highlighted a modest year-over-year increase in Baidu&rsquo;s core revenue for the second quarter but also pointed to a weak advertising outlook. Even though the company&rsquo;s cloud growth is expected to pick up pace, the analyst noted that the monetization of Baidu&rsquo;s artificial intelligence technology is still in the early stages.&nbsp;



Despite a 17% rally in Baidu&rsquo;s stock price, Morgan Stanley sees limited near-term catalysts for further growth. Analysts also noted that while iQIYI, a subsidiary of Baidu, is experiencing cyclical weakness, it is expected to achieve sustainable long-term growth.



Macquarie analyst Ellie Jiang also downgraded Baidu&rsquo;s stock from Outperform to Neutral in a separate move. This additional downgrade by another brokerage firm reflects a broader consensus among analysts regarding Baidu&rsquo;s current market position and future prospects.



On the date of publication, Shane Neagle did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://protect-us.mimecast.com/s/XtC3C1wq33iErOvYSGOsXg?domain=investorplace.com/">Publishing Guidelines</a>.
<div>Shane Neagle is fascinated by the ways in which technology is poised to disrupt investing. He specializes in fundamental analysis and growth investing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/the-analyst-anxiety-index-3-stocks-to-avoid-as-uncertainty-grows/">The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bolt Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bolt-stock-quote/">BOLT</a>) just reported results for the second quarter of 2024.<ul><li>Bolt Biotherapeutics reported earnings per share of -56 cents. This was below the analyst estimate for EPS of -48 cents.</li><li>The company reported revenue of $1.28 million.</li><li>This was 43.02% better than the analyst estimate for revenue of $891,500.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bolt-stock-earnings-bolt-biotherapeutics-for-q2-of-2024/">BOLT Stock Earnings: Bolt Biotherapeutics Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BOLT Stock Earnings: Bolt Biotherapeutics Misses EPS, Beats Revenue for Q2 2024

Bolt Biotherapeutics GAAP EPS of -$0.56, revenue of $1.28M

H.C. Wainwright analyst Edward White maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report) today. The company's shares opened t...

H.C. Wainwright Keeps Their Hold Rating on Bolt Biotherapeutics (BOLT)

Hold Rating on Bolt Biotherapeutics Pending Clarity on Clinical Pipeline and Efficacy Data

Daina Graybosch, an analyst from Leerink Partners, maintained the Hold rating on Bolt Biotherapeutics (BOLT – Research Report). The associated pric...

Bolt Biotherapeutics: Hold Rating Amid Clinical Delays and Restructuring Efforts

Bolt Biotherapeutics (BOLT) just unveiled an update. Bolt Biotherapeutics, Inc. announced board changes with the resignations of James Healy and Fr...

Bolt Biotherapeutics Announces Board Reshuffle and New Appointment

BIDU

Press Releases

BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit

Legal

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Penny Stocks

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

Comments

Bolt Biotherapeutics

Notizie

Ultime notizie per Bolt Biotherapeutics (NASDAQ:BOLT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO